Skip to content
2000
Volume 26, Issue 3
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Background

PD-L1 plays a pivotal role as an immunoregulatory checkpoint within the immune system, exerting a critical influence on the internal functioning and survival mechanisms of cancer cells. Our study aimed to elucidate the clinical significance of PD-L1 expression in circulating tumor cells (CTCs) derived from individuals afflicted with Hypopharyngeal and Laryngeal Cancers (HLC).

Objective

To verify the relationship between the expression of PD-L1 in CTCs in HLC and the consistency in tissue and the preliminary clinical application.

Methods

A laboratory-based experimental study was carried out at Fujian Medical University Union Hospital. CTCs were identified using an immunomagnetic positive sorting methodology. Simultaneous detection was conducted on the CTC levels among PD-L1 positive patients, aiming to ascertain the dynamic relationship between real-time CTC fluctuations and the clinicopathological indices of the patients. This investigation encompassed a cohort of 38 individuals, wherein PD-L1 expression analysis was executed to delineate CTC variations in PD-L1-positive patients.

Results

The constructed immunolipid magnetic nano-beads demonstrated pronounced efficacy in capturing CTCs, and the lipid nanoparticles exhibited noteworthy capture efficiency coupled with minimal cytotoxic effects. The assessment of PD-L1 expression consistency between CTCs and tissue specimens revealed a substantial agreement surpassing 70%. Furthermore, inhibition of PD-L1 yielded a significant elevation in the cytokine TNF-α levels, accompanied by a concomitant reduction in IL-10 levels.

Conclusion

The CTC sorting system devised in this investigation boasts attributes of remarkable specificity and sensitivity. By virtue of PD-L1 expression analysis, it holds the potential to offer instructive implications for tailoring individualized treatments in clinical scenarios.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206340244250605061005
2025-06-12
2026-03-07

  • From This Site

    /content/journals/acamc/10.2174/0118715206340244250605061005
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChaiR.C. LambieD. VermaM. PunyadeeraC. Current trends in the etiology and diagnosis of HPV ‐related head and neck cancers.Cancer Med.20154459660710.1002/cam4.424 25644715
     [Google Scholar]
  2. PrasetyantiP.R. MedemaJ.P. Intra-tumor heterogeneity from a cancer stem cell perspective.Mol. Cancer20171614110.1186/s12943‑017‑0600‑4 28209166
     [Google Scholar]
  3. de SousaV.M.L. CarvalhoL. Heterogeneity in lung cancer.Pathobiology2018851-29610710.1159/000487440 29635240
     [Google Scholar]
  4. ChenW. ZhengR. BaadeP.D. ZhangS. ZengH. BrayF. JemalA. YuX.Q. HeJ. Cancer statistics in China, 2015.CA Cancer J. Clin.201666211513210.3322/caac.21338 26808342
     [Google Scholar]
  5. PantelK. BrakenhoffR.H. Dissecting the metastatic cascade.Nat. Rev. Cancer20044644845610.1038/nrc1370 15170447
     [Google Scholar]
  6. PantelK. SpeicherM.R. The biology of circulating tumor cells.Oncogene201635101216122410.1038/onc.2015.192 26050619
     [Google Scholar]
  7. WooD. YuM. Circulating tumor cells as “liquid biopsies” to understand cancer metastasis.Transl. Res.201820112813510.1016/j.trsl.2018.07.003 30075099
     [Google Scholar]
  8. HabliZ. AlChamaaW. SaabR. KadaraH. KhraicheM.L. Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities.Cancers2020127193010.3390/cancers12071930 32708837
     [Google Scholar]
  9. SharmaS. ZhuangR. LongM. PavlovicM. KangY. IlyasA. AsgharW. Circulating tumor cell isolation, culture, and downstream molecular analysis.Biotechnol. Adv.20183641063107810.1016/j.biotechadv.2018.03.007 29559380
     [Google Scholar]
  10. ParkH. HwangM.P. LeeK.H. Immunomagnetic nanoparticle-based assays for detection of biomarkers.Int. J. Nanomed.2013845434552 24285924
     [Google Scholar]
  11. HatamiG.J.L. HosseiniS.N. AbolhassaniM. GhorbaniM. Progress in affinity ligand-functionalized bacterial magnetosome nanoparticles for bio-immunomagnetic separation of HBsAg protein.PLoS One2022177e026720610.1371/journal.pone.0267206 35877673
     [Google Scholar]
  12. BidardF.C. PeetersD.J. FehmT. NoléF. Gisbert-CriadoR. MavroudisD. GrisantiS. GeneraliD. Garcia-SaenzJ.A. StebbingJ. CaldasC. GazzanigaP. MansoL. ZamarchiR. de LascoitiA.F. De Mattos-ArrudaL. IgnatiadisM. LebofskyR. van LaereS.J. Meier-StiegenF. SandriM.T. Vidal-MartinezJ. PolitakiE. ConsoliF. BottiniA. Diaz-RubioE. KrellJ. DawsonS.J. RaimondiC. RuttenA. JanniW. MunzoneE. CarañanaV. AgelakiS. AlmiciC. DirixL. SolomayerE.F. ZorzinoL. JohannesH. Reis-FilhoJ.S. PantelK. PiergaJ.Y. MichielsS. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data.Lancet Oncol.201415440641410.1016/S1470‑2045(14)70069‑5 24636208
     [Google Scholar]
  13. de BonoJ.S. ScherH.I. MontgomeryR.B. ParkerC. MillerM.C. TissingH. DoyleG.V. TerstappenL.W.W.M. PientaK.J. RaghavanD. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin. Cancer Res.200814196302630910.1158/1078‑0432.CCR‑08‑0872 18829513
     [Google Scholar]
  14. KrebsM.G. SloaneR. PriestL. LancashireL. HouJ.M. GreystokeA. WardT.H. FerraldeschiR. HughesA. ClackG. RansonM. DiveC. BlackhallF.H. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.J. Clin. Oncol.201129121556156310.1200/JCO.2010.28.7045 21422424
     [Google Scholar]
  15. CohenS.J. PuntC.J.A. IannottiN. SaidmanB.H. SabbathK.D. GabrailN.Y. PicusJ. MorseM. MitchellE. MillerM.C. DoyleG.V. TissingH. TerstappenL.W.M.M. MeropolN.J. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.J. Clin. Oncol.200826193213322110.1200/JCO.2007.15.8923 18591556
     [Google Scholar]
  16. AndréT. ShiuK.K. KimT.W. JensenB.V. JensenL.H. PuntC. SmithD. Garcia-CarboneroR. BenavidesM. GibbsP. de la FouchardiereC. RiveraF. ElezE. BendellJ. LeD.T. YoshinoT. Van CutsemE. YangP. FarooquiM.Z.H. MarinelloP. DiazL.A.Jr KEYNOTE-177 investigatorsN. Engl. J. Med.20203832322072218 33264544
     [Google Scholar]
  17. EcksteinM. CimadamoreA. HartmannA. Lopez-BeltranA. ChengL. ScarpelliM. MontironiR. GevaertT. PD-L1 assessment in urothelial carcinoma: A practical approach.Ann. Transl. Med.201972269010.21037/atm.2019.10.24 31930091
     [Google Scholar]
  18. RotmanJ. OtterL.A.S. BleekerM.C.G. SamuelsS.S. HeerenA.M. RoemerM.G.M. KenterG.G. ZijlmansH.J.M.A.A. van TrommelN.E. de GruijlT.D. JordanovaE.S. PD-L1 and PD-L2 expression in cervical cancer: Regulation and biomarker potential.Front. Immunol.20201159682510.3389/fimmu.2020.596825 33424844
     [Google Scholar]
  19. NduomE.K. WeiJ. YaghiN.K. HuangN. KongL.Y. GabrusiewiczK. LingX. ZhouS. IvanC. ChenJ.Q. BurksJ.K. FullerG.N. CalinG.A. ConradC.A. CreasyC. RitthipichaiK. RadvanyiL. HeimbergerA.B. PD-L1 expression and prognostic impact in glioblastoma.Neuro-oncol.201618219520510.1093/neuonc/nov172 26323609
     [Google Scholar]
  20. GhebehH. MohammedS. Al-OmairA. QattantA. LeheC. Al-QudaihiG. ElkumN. AlshabanahM. Bin AmerS. TulbahA. AjarimD. Al-TweigeriT. DermimeS. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors.Neoplasia20068319019810.1593/neo.05733 16611412
     [Google Scholar]
  21. NakanishiJ. WadaY. MatsumotoK. AzumaM. KikuchiK. UedaS. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.Cancer Immunol. Immunother.20075681173118210.1007/s00262‑006‑0266‑z 17186290
     [Google Scholar]
  22. DanZ. DaxiangC. Advances in isolation and detection of circulating tumor cells based on microfluidics.Cancer Biol. Med.201815433535310.20892/j.issn.2095‑3941.2018.0256 30766747
     [Google Scholar]
  23. WennenhuisJ.F. Van DalumG. ZeuneL.L. TerstappenL.W. Improving the CellSearch® system.Expert Rev. Mol. Diagn.201616121291130510.1080/14737159.2016.1255144 27797592
     [Google Scholar]
  24. WangL. BalasubramanianP. ChenA.P. KummarS. EvrardY.A. KindersR.J. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.Semin. Oncol.201643446447510.1053/j.seminoncol.2016.06.004 27663478
     [Google Scholar]
  25. YiB. WuT. ZhuN. HuangY. YangX. YuanL. WuY. LiangX. JiangX. The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma.J. Nanobiotechnol.20211917410.1186/s12951‑021‑00818‑3 33726759
     [Google Scholar]
  26. BrodyR. ZhangY. BallasM. SiddiquiM.K. GuptaP. BarkerC. MidhaA. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.J. Lung Cancer201711220021510.1016/j.lungcan.2017.08.005
     [Google Scholar]
  27. LuchiniC. BibeauF. LigtenbergM.J.L. SinghN. NottegarA. BosseT. MillerR. RiazN. DouillardJ.Y. AndreF. ScarpaA. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach.Ann. Oncol.20193081232124310.1093/annonc/mdz116 31056702
     [Google Scholar]
  28. ŠmahelM. PD-1/PD-L1 blockade therapy for tumors with downregulated MHC class I expression.Int. J. Mol. Sci.2017186133110.3390/ijms18061331 28635644
     [Google Scholar]
  29. MazelM. JacotW. PantelK. BartkowiakK. TopartD. CayrefourcqL. RossilleD. MaudelondeT. FestT. Alix-PanabièresC. Frequent expression of PD‐L1 on circulating breast cancer cells.Mol. Oncol.2015991773178210.1016/j.molonc.2015.05.009 26093818
     [Google Scholar]
  30. JilaveanuL.B. ShuchB. ZitoC.R. ParisiF. BarrM. KlugerY. ChenL. KlugerH.M. PD-L1 expression in clear cell renal cell carcinoma: An analysis of nephrectomy and sites of metastases.J. Cancer20145316617210.7150/jca.8167 24563671
     [Google Scholar]
  31. AllardW.J. MateraJ. MillerM.C. RepolletM. ConnellyM.C. RaoC. TibbeA.G.J. UhrJ.W. TerstappenL.W.M.M. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.Clin. Cancer Res.200410206897690410.1158/1078‑0432.CCR‑04‑0378 15501967
     [Google Scholar]
  32. WarkianiM.E. GuanG. LuanK.B. LeeW.C. BhagatA.A.S. Kant ChaudhuriP. TanD.S.W. LimW.T. LeeS.C. ChenP.C.Y. LimC.T. HanJ. Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells.Lab Chip201414112813710.1039/C3LC50617G 23949794
     [Google Scholar]
  33. KhooB.L. WarkianiM.E. TanD.S.W. BhagatA.A.S. IrwinD. LauD.P. LimA.S.T. LimK.H. KrisnaS.S. LimW.T. YapY.S. LeeS.C. SooR.A. HanJ. LimC.T. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.PLoS One201497e9940910.1371/journal.pone.0099409 24999991
     [Google Scholar]
  34. ChenS. CrabillG.A. PritchardT.S. McMillerT.L. WeiP. PardollD.M. PanF. TopalianS.L. Mechanisms regulating PD-L1 expression on tumor and immune cells.J. Immunother. Cancer20197130510.1186/s40425‑019‑0770‑2 31730010
     [Google Scholar]
  35. PengS. WangR. ZhangX. MaY. ZhongL. LiK. NishiyamaA. AraiS. YanoS. WangW. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.Mol. Cancer201918116510.1186/s12943‑019‑1073‑4 31747941
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206340244250605061005
Loading
Determination of PD-L1 Expression in Circulating Tumor Cells of Hypopharyngeal and Laryngeal Cancers and Correlation with Tissue Detection
Anti-Cancer Agents in Medicinal Chemistry 26, 278 (2026); https://doi.org/10.2174/0118715206340244250605061005
/content/journals/acamc/10.2174/0118715206340244250605061005
/content/journals/acamc/10.2174/0118715206340244250605061005
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): CTCs; genomic mutations; Hypopharyngeal and laryngeal cancers; immunotherapy; PD-L1; tumorigenesis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test